Intercell Plans to Achieve Turnaround in 2014
The Vienna-listed pharmaceutical company Intercell expects to return to the profit zone in 2014.
“2014 will become a break-even year.” says CEO Thomas Lingelbach in an interview with the Austrian newspaper Wirtschaftsblatt. Intercell disposes of adequate funds in order to bridge the two years. “We will achieve that and it is expectable that we are on the positive side of our guidance.”, Lingelbach underlines.
Last year, Intercell had to report losses of € 30m to…